Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference

Thursday, September 1, 2016 8:05 PM UTC

FORT WASHINGTON, Pa., Sept. 01, 2016 -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2016 at 1:10 p.m. EDT at the Westin Boston Waterfront.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A replay of the webcast will be archived on Vitae's website for 90 days following the presentation.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, VTP-45489, a second and chemically distinct RORyt inhibitor being studied for its potential in autoimmune disorders, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company's website at www.vitaepharma.com.

INVESTORS:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
[email protected]

Westwicke Partners
John Woolford
(443) 213-0506
[email protected]

MEDIA:
6 Degrees PR
Tony Plohoros 
(908) 591-2839
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference

Editor's Picks

Welcome to EconoTimes